Pereira, Manuel Pedro
Wiegmann, Henning
Ständer, Sonja
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FOR2690)
Article History
Received: 29 July 2022
Revised: 26 September 2022
Accepted: 22 November 2022
First Online: 2 January 2023
Competing interests
: S.S. was supported by the German Research Foundation (DFG, No. FOR2690). S.S. is an investigator for Celldex, Clexio, Dermasence, Galderma, GSK, Kiniksa, Novartis, Sanofi, Trevi, and is a speaker, consultant and/or member of the advisory board for Abbvie, Almirall, Beiersdorf, Bellus Health, Benevolent, Bionorica, BMS, Cara, Clexio, DS Biopharma, Eli Lilly, Escient, Galderma, Grünenthal, Kiniksa, Klinge Pharma, Leo Pharma, L’Oréal, Novartis, Omnicuris, Pfizer, Sanofi, Symbio Research, Trevi, UCB, Vifor. H.W. declares no potential competing interests. M.P.P. is an investigator for Sanofi and Trevi Therapeutics; is a consultant for Galderma; and has received speaker honoraria/travel fees from AbbVie, Beiersdorf, Eli Lilly, Galderma, Menlo Therapeutics, Novartis, P.G. Unna Academy and Trevi Therapeutics.